Bayer’s best-selling stroke prevention drug Xarelto contributed to the positive surprise with a better-than-expected 933 million euros in quarterly sales, helped by a wider range of health conditions for which the pill can be prescribed.
Bayer’s best-selling stroke prevention drug Xarelto contributed to the positive surprise with a better-than-expected 933 million euros in quarterly sales, helped by a wider range of health conditions for which the pill can be prescribed.